Tissue Allograft Improves Ulcer Outcomes
In a recently published study, treatment with EpiFix (MiMedx Group, Inc, Marietta, GA) was found to be more effective for wound closure than standard of care (SOC). The dehydrated human amnion/chorion membrane (dHACM) was compared in 2 different cohorts of nonhealing diabetic foot ulcers (DFUs). In the intent-to-treat population, 70% of patients receiving weekly dHACM treatment had complete healing by 12 weeks versus 50% of patients receiving SOC only. Similarly, in the per-protocol cohort, 81% of patients treated with weekly dHACM achieved complete healing in 12 weeks, compared with only 55% of patients treated with SOC. Cox regression analysis showed dHACM was twice as likely to heal DFUs within 12 weeks than treatment with SOC.
Visit www.mimedx.com for more information.